Company Overview and News


Add TSRO
to your dashboard

Headline News

U.S. Biotech/Pharma Sector Daily Observations Letter: Jan. 18, 2018

23h seekingalpha
U.S. hospital systems to partner in order to create their own generic drugs business to save rising generic drug costs. (366-0)

Your Daily Pharma Scoop: Eiger Selloff, Novartis' Cosentyx, RXi Outlines Business Strategy

2018-01-17 seekingalpha
Today we will discuss the results from the phase 2 LIBERTY Study announced by clinical stage biopharmaceutical company, Eiger Biopharmaceuticals (EIGR). (62-0)

Southern Company, Tesaro Plunge into Monday’s 52-Week Low Club

2018-01-16 247wallst
January 12, 2018: Here are four stocks trading with heavy volume among 30 equities making new 52-week lows in Tuesday’s session. On the NYSE decliners led advancers by nearly 2 to 1 and on the Nasdaq, advancers led decliners by slightly more than 2 to 1. (11-0)

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)

Clovis - Promise For 2018 Looks Good

2018-01-14 seekingalpha
After years of M&A interest and worries about product approval, Clovis has started to market Rucaparib in 2017, as the pick-up in sales is disappointing. (77-1)

BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion

2018-01-12 reuters
* TESARO INC - CHANGES TO LABELING INCLUDE MODIFICATIONS TO CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, AND ADVERSE REACTIONS SECTIONS (10-0)

ROTY Edition 1 Volume 67: Starting January On A Strong Note

2018-01-03 seekingalpha
ROTY had a solid December and January appears to be starting on a strong note as well. (107-1)

Edison International, Windstream Topple into Tuesday’s 52-Week Low Club

2018-01-02 247wallst
January 2, 2018: Here are four stocks trading with heavy volume among 36 equities making new 52-week lows in Tuesday’s session. On the NYSE advancers led decliners by about 3 to 2 and on the Nasdaq, advancers and decliners by more than 2 to 1. (22-1)

Clovis Up More Than 50% in 2017: What's Driving the Stock?

2017-12-28 zacks
Shares of Clovis Oncology, Inc. (CLVS - Free Report) have been on a roll. This small biotech company is up 51.2% so far this year, outperforming the 3.5% increase registered by the industry during this period. (80-1)

US cancer drugmaker Ignyta in advanced sale talks: Sources - Channel NewsAsia

2017-12-22 channelnewsasia
REUTERS: Ignyta Inc is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focused on precision drugs and diagnostics. (105-1)

Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks - sources

2017-12-22 in.reuters
(Reuters) - Ignyta Inc (RXDX.O) is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focussed on precision drugs and diagnostics. (105-0)

Free Research Report as Tesaro’s Revenue Rocketed 740%

2017-12-21 accesswire
LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free earnings report on Tesaro, Inc. (NASDAQ: TSRO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=TSRO . The Company reported its third quarter fiscal 2017 operating results on November 07, 2017. The biopharmaceutical Company's net loss narrowed on a y-o-y basis, while it surpassed top- and bottom-line expectations. (11-0)

Biotech Forum Daily Digest: Aerie Pharmaceuticals Garners Early FDA Approval

2017-12-20 seekingalpha
The biotech sector is set to wrap up a solid year in 2017.  Tax reform could spark a noticeable uptick in M&A in 2018. (42-0)

Your Daily Pharma Scoop: Aclaris Gets Approval, Egalet Surges, Alnylam Gains As FDA Lifts Clinical Hold

2017-12-17 seekingalpha
Today we will focus on Aclaris Therapeutics (ACRS). As we had expected, the FDA has approved its ESKATA topical solution, 40% for the treatment of raised seborrheic keratosis (non-cancerous skin growth). We had noted in our recent article that based on the data, an approval was likely. And as we expected, the stock has seen a pullback post approval. (142-3)

CUSIP: 881569107